JP2018525345A5 - - Google Patents

Download PDF

Info

Publication number
JP2018525345A5
JP2018525345A5 JP2017568029A JP2017568029A JP2018525345A5 JP 2018525345 A5 JP2018525345 A5 JP 2018525345A5 JP 2017568029 A JP2017568029 A JP 2017568029A JP 2017568029 A JP2017568029 A JP 2017568029A JP 2018525345 A5 JP2018525345 A5 JP 2018525345A5
Authority
JP
Japan
Prior art keywords
group
alkyl
compound
halo
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017568029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525345A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/040467 external-priority patent/WO2017004405A1/en
Publication of JP2018525345A publication Critical patent/JP2018525345A/ja
Publication of JP2018525345A5 publication Critical patent/JP2018525345A5/ja
Pending legal-status Critical Current

Links

JP2017568029A 2015-07-01 2016-06-30 置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用 Pending JP2018525345A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562187461P 2015-07-01 2015-07-01
US62/187,461 2015-07-01
PCT/US2016/040467 WO2017004405A1 (en) 2015-07-01 2016-06-30 Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity

Publications (2)

Publication Number Publication Date
JP2018525345A JP2018525345A (ja) 2018-09-06
JP2018525345A5 true JP2018525345A5 (enExample) 2019-08-08

Family

ID=57609612

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017568029A Pending JP2018525345A (ja) 2015-07-01 2016-06-30 置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用

Country Status (5)

Country Link
US (3) US10167270B2 (enExample)
EP (1) EP3317265A4 (enExample)
JP (1) JP2018525345A (enExample)
CN (1) CN108290855A (enExample)
WO (1) WO2017004405A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073889A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
CN107001379B (zh) 2014-11-06 2022-11-01 Bial研发投资股份有限公司 取代的吡唑并[1,5-a]嘧啶以及它们在治疗医学障碍中的用途
AU2015342883B2 (en) 2014-11-06 2020-07-02 Bial - R&D Investments, S.A. Substituted pyrrolo(1,2-a)pyrimidines and their use in the treatment of medical disorders
JP2018525345A (ja) * 2015-07-01 2018-09-06 ノースウェスタン ユニバーシティ 置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用
WO2017091661A1 (en) * 2015-11-25 2017-06-01 Strovel Jeffrey William Bicyclic bet bromodomain inhibitors and uses thereof
MX2021006804A (es) 2015-12-17 2023-01-13 Merck Patent Gmbh Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
WO2017176960A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
US10787454B2 (en) 2016-04-06 2020-09-29 BIAL—BioTech Investments, Inc. Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
WO2017176962A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics, Inc. Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
WO2017192931A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
MX389579B (es) 2016-05-05 2025-03-20 Bial R&D Invest S A IMIDAZO[1,2-b]PIRIDAZINAS SUSTITUIDAS, IMIDAZO[1,5-b]PIRIDAZINAS SUSTITUIDAS, COMPUESTOS RELACIONADOS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MÉDICOS
EP4198031A1 (en) 2016-08-08 2023-06-21 Merck Patent GmbH Tlr7/8 antagonists and uses thereof
FI3612030T3 (fi) 2017-04-21 2026-03-20 Pahr Therapeutics Inc Ahr:n indoliestäjiä ja niiden käyttötapoja
US12291533B2 (en) 2017-08-02 2025-05-06 Northwestern University Substituted fused pyrimidine compounds and uses thereof
SG11202100818RA (en) * 2018-07-31 2021-02-25 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
US10882865B2 (en) 2018-08-31 2021-01-05 Northwestern University Pyrrolopyrimidine compounds and uses thereof for modulating glucocerebrosidase activity
MX2021004245A (es) * 2018-10-16 2021-09-08 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
MX2022006308A (es) 2019-11-26 2022-06-22 Ikena Oncology Inc Derivados de carbazol polimorfos y usos de los mismos.
US20240166669A1 (en) * 2021-03-05 2024-05-23 Nikang Therapeutics, Inc. Quinazoline amine derivatives as kras inhibitors
US20240262832A1 (en) * 2021-04-30 2024-08-08 Vanqua Bio, Inc. Small molecule modulators of glucocerebrosidase activity and uses thereof
WO2022232360A1 (en) * 2021-04-30 2022-11-03 Vanqua Bio, Inc. Small molecule modulators of glucocerebrosidase activity and uses thereof
WO2023025109A1 (zh) * 2021-08-23 2023-03-02 上海维申医药有限公司 一类Toll样受体抑制剂及其制备和应用
WO2023064345A1 (en) * 2021-10-13 2023-04-20 Vanqua Bio, Inc. Small molecule modulators of glucocerebrosidase activity and uses thereof
TW202509030A (zh) * 2023-05-08 2025-03-01 美商譚格醫療公司 化合物及使用方法
WO2026020056A1 (en) * 2024-07-18 2026-01-22 Neumora Therapeutics, Inc. Compounds and methods for treating neurological disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1003299A (en) 1910-08-06 1911-09-12 Basf Ag Process and apparatus for producing long stable electric arcs.
DE831249C (de) * 1948-02-09 1952-02-11 Ciba A G Verfahren zur Herstellung heterocyclisch substituierter Diaminochinazoline
BE553585A (enExample) * 1955-12-21
GB1582407A (en) * 1977-06-07 1981-01-07 Worcester Controls Uk Ltd Annular seals
AU1071301A (en) * 1999-11-01 2001-05-14 Eli Lilly And Company Pharmaceutical compounds
US8338420B1 (en) * 2002-12-04 2012-12-25 Mitsubishi Tanabe Pharma Corporation Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
WO2004092196A2 (en) * 2003-04-09 2004-10-28 Exelixis, Inc. Tie-2 modulators and methods of use
CN101115736A (zh) * 2005-03-14 2008-01-30 神经研究公司 钾通道调节剂和它们的医药用途
EP1966184B1 (en) * 2005-12-20 2010-08-25 NeuroSearch A/S Pyridinyl-quinazoline derivatives and their medical use
AU2006329202A1 (en) * 2005-12-21 2007-06-28 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
WO2009049421A1 (en) * 2007-10-18 2009-04-23 The Hospital For Sick Children Compositions and methods for enhancing enzyme activity in gaucher, gm1-gangliosidosis/morquio b disease, and parkinson's disease
JP2011513483A (ja) * 2008-03-10 2011-04-28 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン
WO2010120987A1 (en) * 2009-04-17 2010-10-21 Wyeth Llc Ring fused, ureidoaryl- and carbamoylaryl-bridged morpholino-pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
US20140031547A1 (en) * 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
CN103917094B (zh) * 2011-03-18 2016-11-09 建新公司 葡萄糖基神经酰胺合酶抑制剂
KR20150065157A (ko) * 2013-12-04 2015-06-12 에스에프씨 주식회사 유기발광 화합물 및 이를 포함하는 유기전계발광소자
CN104693211A (zh) * 2013-12-10 2015-06-10 南京明德新药研发股份有限公司 作为抗病毒剂的咪唑衍生物及其制药用途
BR112016012129A8 (pt) * 2013-12-11 2020-05-12 Pfizer Ltd métodos para produção, expansão e purificação de células epiteliais do pigmento da retina, composição farmacêutica e uso das células
CN105431424B (zh) * 2013-12-18 2019-09-06 出光兴产株式会社 化合物、有机电致发光元件用材料、油墨组合物、有机电致发光元件、电子机器及制造方法
CN108290894A (zh) 2015-07-01 2018-07-17 西北大学 被取代的4-甲基-吡咯并[1,2-a]嘧啶-8-甲酰胺类化合物及其调节葡糖脑苷脂酶活性的用途
JP2018525345A (ja) 2015-07-01 2018-09-06 ノースウェスタン ユニバーシティ 置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用
US10882865B2 (en) 2018-08-31 2021-01-05 Northwestern University Pyrrolopyrimidine compounds and uses thereof for modulating glucocerebrosidase activity

Similar Documents

Publication Publication Date Title
JP2006206609A5 (enExample)
JP2016503799A5 (enExample)
RU2475487C2 (ru) Имидазохинолины с иммуномодулирующими свойствами
JP2017513894A5 (enExample)
JP2016514159A5 (enExample)
IL291590B1 (en) Novel modified quinoline-8-carbonitrile compounds with androgen receptor unblocking activity and their uses
JP2014508804A5 (enExample)
JP2017503760A5 (enExample)
PE20161400A1 (es) Derivados de isoindolin-1-ona con actividad positiva del modulador alosterico del receptor colinergico muscarinico m1 para el tratamiento de la enfermedad de alzheimer
PE20091008A1 (es) Derivados heterociclicos como moduladores de fosfoinositida 3-cinasa
JP2006524222A5 (enExample)
PE20070189A1 (es) COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA
JP2012502974A5 (enExample)
JP2015509535A5 (enExample)
JP2016501250A5 (enExample)
JP2016513660A5 (enExample)
JP2005529926A5 (enExample)
CO5550451A2 (es) Derivados de 3-(sulfonamidoetil)-indol para uso como mimeti- cos de glucocorticoides en el tratamiento de enfermedades inflamatorias, alergicas y proliferativas
HRP20141190T1 (hr) Disupstituirani derivati piridina kao antikancerogena sredstva
JP2017518334A5 (enExample)
PE20090617A1 (es) Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
PE20091527A1 (es) Derivados de piridazinona
RU2015146957A (ru) Производные доластатина 10 и ауристатинов
PE20210641A1 (es) COMPUESTOS DIOLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-y
JP2010535790A5 (enExample)